RAISE Community Workshop Series Workshop 10
June 1, 2023

Speakers

Oscar Benavidez, MD, MBA, MPP
Managing Director/Chief Congenital Cardiology and DEI Director
Massachusetts General Hospital

Dr. Oscar J. Benavidez is the Division Chief of Pediatric/Congenital Cardiology and the Medical Director of the Pediatric Cardiac Catheterization and Surgical Programs at Massachusetts General Hospital. Dr. Benavidez is also the Director of Diversity and Equity at Mass General Hospital for Children. His clinical area of expertise is Non-Invasive Congenital Cardiac Imaging from fetus to adult patients with congenital heart disease. Dr. Benavidez is involved in health services research and has published on topics related to patient safety and quality as it pertains to the care of patients with congenital heart disease. He is also on national committees that develop and implement quality measures.

Elise Berliner, PhD
Global Senior Principal for Real World Evidence Strategy
Cerner Enviza

Dr. Elise Berliner is the Global Senior Principal for Real World Evidence Strategy at Cerner Enviza. Before joining Cerner Enviza, Dr. Berliner was the Director of the Technology Assessment Program at the Agency for Healthcare Research and Quality (AHRQ), providing systematic reviews and other scientific analyses to the Centers for Medicare & Medicaid Services (CMS) to inform Medicare coverage decisions and other policy issues. Dr. Berliner has several years of experience in research and development at innovative medical technology companies, was a Fellow at the Office of Technology Assessment in the United States Congress, and received her doctoral degree in biophysics from Brandeis University.

Louis Cabanilla
Director of Corporate Data and Analytics
Point32 Health

Louis Cabanilla has a healthcare analytics career that spans payor, provider, pharma, and policy. Over the past six years with Point32Health, Louis designed and implemented analytic solutions to drive Population Health and Health Equity initiatives. Through collaboration with academic collaborations at the Harvard Pilgrim Health Care Institute the Enterprise Segmentation and Stratification tool was developed to identify unmet needs in populations, to create algorithms to match members to interventions, to drive processes to measure program effectiveness, and to build predictive models. Most recently, Louis led the development of a composite Social Inequality Index for all Point32Health members leveraging geospatial analytics which has enabled the company to pinpoint actions for their Health Equity initiatives. Louis is passionate about analytics and how it can be leveraged to unlock equity in healthcare. He has a special interest in addressing health literacy in marginalized communities to improve preventative care. Louis received an MSc in Health Economics from Erasmus University (Rotterdam, The Netherlands), and a BA in Economics from the University of Colorado at Boulder.

Alecia Clary, PhD, MSW
Founder and CEO, Evidence to Practice
Co-Investigator, RAISE

Dr. Alecia Clary is the founder and CEO of Evidence to Practice, a consulting and advisory services firm that provides clients expert research, policy, and operations support to accelerate the adoption of health care innovations. She also serves as a co-investigator on the RAISE project and leading the development of the RAISE roadmap and the RAISE program evaluation. She is a health services researcher and implementation scientist by trade.

Prior to founding Evidence to Practice, Dr. Clary served as the Associate Director of Research for the Reagan-Udall Foundation for the FDA. She held previous roles as a research scientist at Avalere Health, where she designed and conducted studies focused on using real-world evidence to evaluate and improve healthcare quality, and as both a research analyst and health science specialist at the Durham VAMC. Dr. Clary earned a doctoral degree from the Gillings School of Global Public Health at UNC Chapel Hill, a master's degree from the UNC School of Social Work, and a bachelor's degree in Sociology from UNC Chapel Hill.

Rachele Hendricks-Sturrup, DHSc, MSc, MA
Research Director of Real-World Evidence (RWE)
Duke-Margolis Center for Health Policy

Dr. Rachele Hendricks-Sturrup is the Research Director of Real-World Evidence (RWE) at the Duke-Margolis Center for Health Policy in Washington, DC, strategically leading and managing the Center's RWE Collaborative. As an engagement expert, researcher, bioethicist, and policy practitioner, her work centers on addressing implementation and ethical, legal, and social implications issues at the intersection of health policy and innovation. She also partners with Duke University faculty, scholars, students, and external health experts to advance the Center's biomedical innovation work. She is presently adjunct faculty at rural Ohio University, teaching graduate courses in the Department of Interdisciplinary Health Science's Health Policy Certificate program, and has taught graduate courses within the Masters of Health Care Innovation program at the University of Pennsylvania's Perelman School of Medicine.

Prior to joining Duke-Margolis, Dr. Hendricks-Sturrup was Health Policy Counsel and Lead at the Future of Privacy Forum (FPF), leading the organization's health and genetic data initiatives and workgroup. Prior to FPF, she served in several administrative and scientific roles at various industry, health care, and academic institutions. To date, she has published several commentaries and original research papers in high-quality, peer-reviewed journals. Dr. Hendricks-Sturrup is also an accomplished health and science journalist, having completed a comparative effectiveness research fellowship with the Association of Health Care Journalists in 2017.

Dr. Hendricks-Sturrup received her bachelor’s degree in Biology from Chicago State University, her master’s degree in Pharmacology and Toxicology from Michigan State University, her master’s in Legal Studies from the University of Illinois, and her doctoral degree in Health Science from Nova Southeastern University. She completed a predoctoral internship with the National Health Service in London, UK, and postdoctoral research training within the Department of Population Medicine at Harvard Pilgrim Health Care Institute and Harvard Medical School.

Sandy Leonard
Chief Commercial Officer, COTA, Inc.
Expert Panel Member, RAISE

Sandy Leonard is the chief commercial officer of COTA, Inc. Prior to joining COTA, Sandy was the Senior Vice President of Partnership and Real-World Data at HealthVerity. There she was responsible for driving strategic partner relationships, growing government engagements, and expanding the team that brought real-world data expertise to HealthVerity's clients.

Before her time with HealthVerity, Sandy was the Vice President, Medical Evidence and Observational Research at AstraZeneca where she led a global team of real-world evidence scientists and study delivery professionals who together delivered impactful evidence for the entirety of the AstraZeneca portfolio.

RAISE FDA & FDA Foundation Team

RDML Richardae Araojo, PharmD, MS
Associate Commissioner for Minority Health, Director
Office of Minority Health and Health Equity, U.S. Food and Drug Administration

Rear Admiral Richardae Araojo, PharmD, MS, serves as the Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity at the U.S. Food and Drug Administration (FDA). In this role, RDML Araojo provides leadership, oversight, and direction on minority health and health disparity matters for the Agency. RDML Araojo previously served as the Director of the Office of Medical Policy Initiatives in FDA's Center for Drug Evaluation and Research (CDER), where she led a variety of broad-based medical and clinical policy initiatives to improve the science and efficiency of clinical trials and enhance professional and patient labeling. RDML Araojo joined FDA in 2003, where she held several positions in CDER. RDML Araojo received her doctoral degree in Pharmacy from Virginia Commonwealth University, completed a Pharmacy Practice Residency at University of Maryland, and earned a master's degree in Pharmacy Regulation and Policy from the University of Florida.

Carla Rodriguez-Watson, PhD, MPH
Director of Research
Reagan-Udall Foundation for the FDA

Dr. Carla Rodriguez-Watson is the Director of Research for the Reagan-Udall Foundation for the FDA. Dr Rodriguez-Watson is focused on continuously developing and enhancing a portfolio of work that leverages real-world data and experiences to inform and conduct clinical and post-market drug safety and effectiveness studies. Projects include those focused on developing and advancing frameworks and tools to systematically describe data sources and methods for use in pre and post-market studies of product safety and effectiveness; as well as the the Innovation in Medical Evidence, Development and Surveillance (IMEDS) Program – where such tools can be leveraged. IMEDS leverages a distributed network and tools developed by the FDA's Sentinel initiative to design and execute post-market drug safety studies in a network of 9 healthcare systems representing over 111 M persons. Dr. Rodriguez-Watson brings her extensive background in public health surveillannce and health outcomes research to this work. She earned her doctoral degree in Epidemiology from the University of Washington School of Public Health, her master's degree in Public Health from Columbia University Mailman School of Public Health, and her bachelor's degree from Rutgers University.

Susan C. Winckler, RPh, Esq.
CEO
Reagan-Udall Foundation for the FDA

Susan C. Winckler is CEO of the Reagan-Udall Foundation for the FDA, the non-profit organization created by Congress to advance the mission of the FDA. Prior to accepting the Foundation post, she served as President of Leavitt Partners Solutions, a healthcare strategy firm founded by Gov. Michael O. Leavitt, former Secretary of the U.S. Department of Health and Human Services. Winckler directly advised C-suite executives of a wide range of organizations on public policy and regulation, business strategy, investments, and other major business matters. As Chief of Staff for the U.S. Food and Drug Administration (2007-2009), she managed the Commissioner's Office, served both Republican and Democratic commissioners as their senior-most staff adviser, analyzed complex policy challenges and represented FDA with myriad government entities and external stakeholders. Her earlier career service included more than a decade at the American Pharmacists Association in a series of positions of increasing responsibility.